Document is current
Any future updates will be listed below
-
Authors
Ziccheddu, Bachisio
Giannotta, Claudia
D’Agostino, Mattia
Bertuglia, Giuseppe http://orcid.org/0009-0009-3785-9824
Saraci, Elona
Oliva, Stefania
Genuardi, Elisa
Papadimitriou, Marios
Diamond, Benjamin http://orcid.org/0000-0002-8638-9365
Corradini, Paolo http://orcid.org/0000-0002-9186-1353
Coffey, David
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Bolli, Niccolò
Bruno, Benedetto
Boccadoro, Mario http://orcid.org/0000-0001-8130-5209
Massaia, Massimo
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Larocca, Alessandra
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA 240139)
Associazione Italiana per la Ricerca sul Cancro (AIRC IG 20541, AIRC IG 20541)
- License Information
-
More Information
Article History
Received: 13 February 2024
Revised: 1 July 2024
Accepted: 8 July 2024
First Online: 19 July 2024
Competing interests
: OL has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Myeloma Solutions Fund (MSF), Paula and Rodger Riney Multiple Myeloma Research Program Fund, the Tow Foundation, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. FM has received honoraria from Medidata. NB has received honoraria from Janssen, Pfizer, GSK, Jazz, Takeda. The remaining authors declare no competing interests. MD has received honoraria from GlaxoSmithKline, Sanofi, and Janssen; has served on the advisory boards for GlaxoSmithKline, Sanofi, Adaptive Biotechnologies and Bristol Myers Squibb. SO has received honoraria from Amgen, Celgene/Bristol Myers Squibb, Janssen, Sanofi; has served on the advisory boards for Pfizer, Adaptive Biotechnologies, Janssen, Amgen, Takeda, and Sanofi. BB has received honoraria from Amgen, Janssen, Novartis, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Jazz pharmaceuticals, Astrazeneca and Incyte; has served on the advisory boards for Amgen and Jazz pharmaceuticals. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GlaxoSmithKline; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. AL has received honoraria and served on the advisory board from Janssen-Cilag, BMS, Amgen, Takeda, Oncopeptides, GSK, Sanofi and Karyopharm.
: The study was conducted in accordance with the Declaration of Helsinki. All samples were collected after informed consent approved by the Comitato Etico Interaziendale AOU Città della Salute e della Scienza di Torino (ID: act 26/2023/XI).
